Pharma BD Deal Intelligence
Incyte never acquired MacroGenics — this was a $150M upfront licensing deal for one PD-1 asset (retifanlimab/Zynyz), which took over 5 years to reach first approval and remains a modest, sub-blockbuster product; MacroGenics stayed fully independent throughout.
Full analysis, sources & comparables →Incyte secured a late-mover PD-1 in MGA012 from MacroGenics, betting that niche-tumor positioning and combination strategies with its IDO and JAK pipeline…
FDA issued a CRL for retifanlimab in anal cancer following a negative advisory panel that questioned the single-arm Phase 2 data as insufficient — a major…
FDA approved Zynyz (retifanlimab-dlwr) plus platinum chemotherapy as the first frontline regimen for advanced SCAC based on Phase 3 POD1UM-303 data showing…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Incyte licensed worldwide rights to develop and commercialize MGA012, MacroGenics' anti-PD-1 monoclonal antibody, in all indications. MacroGenics received $150M upfront plus eligibility for up to $420M in development/regulatory milestones and up to $330M in commercial milestones (~$900M total) plus tiered 15-24% royalties on net sales. MacroGenics retained rights to use MGA012 in combination with its proprietary pipeline.
Incyte never acquired MacroGenics — this was a $150M upfront licensing deal for one PD-1 asset (retifanlimab/Zynyz), which took over 5 years to reach first approval and remains a modest, sub-blockbuster product; MacroGenics stayed fully independent throughout.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / MacroGenics, Inc. (this deal) | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2017 deals · Incyte Corporation deals · Hematology deals